Who We Are

Isarna Therapeutics was built on profound knowledge in antisense oligonucleotide design and therapeutic development of this innovative compound class. Today, Isarna is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology -    TGF-β signaling. Precise modulation of TGF-β pathways using antisense therapy may result in safer and more effective treatment options for a broad range of indications.

Our lead compound, ISTH0036, is in Phase 2a clinical development in Ophthalmology. In addition, Isarna has established a portfolio of antisense compounds addressing three important isoforms of TGF-β to treat fibrotic liver disease, such as NASH, and various forms of cancer.

Learn more about
our TGF-BETA pipeline


TGF-Beta is a key mediator of fibrosis in the eye and in many other organs like liver and lung..


Isarna has a pipeline of different antisense molecules blocking the production of TGF-Beta


A clinical Phase 2a study in nAMD and DME is ongoing. Details can be found at https://www.clinicaltrialsregister.eu


Funded by a committed team of investors

MIG Fonds Refit GAF GCF Bayern Kapital KFW

Join Our Team

If you want to join a pioneering company developing life-changing medication, please contact us.

News & Events

Find out more about Isarna and be up-to-date with our News, Events & Press Releases.